United States Patent 10,314,780: Bimatoprost Ophthalmic Gel Claims, Patent Scope and Competitive Landscape

US Patent 10,314,780 protects a drippable ophthalmic gel containing bimatoprost, a polyacrylate, a secondary viscosity or film-forming polymer, an isotonicity agent, a viscosity-adjusting salt, a pH-adjusting base and water. The broadest claim is a tightly defined formulation claim requiring simultaneous compliance with concentration, pH, osmolality, viscosity and excipient limitations.

The patent is materially different from conventional bimatoprost ophthalmic solutions such as Lumigan because it requires a gel system with a measured viscosity of 200 to 2,000 mPa·s. The principal infringement risk concerns products using carbomer or another high-molecular-weight polyacrylate together with povidone or a related polymer.

What does US Patent 10,314,780 cover?

US 10,314,780 covers three related subject-matter groups:

A drippable bimatoprost ophthalmic gel.
Containers holding the gel, including preservative-free single-dose units and preserved multidose plastic containers.
Manufacturing and therapeutic-use methods involving the gel.

The patent issued on June 11, 2019. Its term is generally expected to run into 2034, calculated from the earliest effective nonprovisional priority date, subject to any patent-term adjustment or other term calculation under the official USPTO record.[1]

Core formulation limitations

Claim 1 limitation	Required scope
Bimatoprost	0.003% to 0.03% by weight
Polyacrylate	More than 0.2% by weight
Secondary polymer	Povidone, dextran, polyethylene glycol, carboxymethyl cellulose or poly(vinyl alcohol), 0.2% to 10.0%
Isotonizing agent	Sufficient to produce 200 to 400 mOsm/kg
Viscosity-adjusting salt	0.05% to 0.4%
pH-adjusting base	pH 6 to 8
Water	Required
Viscosity	200 to 2,000 mPa·s
Measurement method	Brookfield RVDV-II Viscometer at 25°C

Every limitation must be satisfied for literal infringement of claim 1. A formulation outside any required range may avoid claim 1, although dependent claims, equivalents and other family patents must be assessed separately.

How broad is claim 1 of US 10,314,780?

Claim 1 is broad in the identity of the excipients but narrow in its cumulative technical requirements.

The claim does not require one particular polyacrylate trade name. It can potentially cover different carbomer or polyacrylic-acid materials, provided the material qualifies as a polyacrylate and is present at more than 0.2% by weight. Claim 8 narrows the polyacrylate to materials with a molecular weight of 1,000,000 to 4,000,000.

The secondary polymer is defined through a Markush group. The claim can be met with any one of the following:

Povidone;
Dextran;
Polyethylene glycol;
Carboxymethyl cellulose; or
Poly(vinyl alcohol).

The claim therefore does not require povidone specifically. A competitor using polyethylene glycol or carboxymethyl cellulose may still fall within claim 1 if the other limitations are satisfied.

Why the viscosity limitation matters

The 200 to 2,000 mPa·s viscosity range is a central limitation. The specification requires measurement using a Brookfield RVDV-II Viscometer at 25°C. Viscosity is not merely a formulation result; it is an express claim limitation and must be tested under a comparable method.

A product described commercially as a “gel” may not infringe if its viscosity is below 200 mPa·s. Conversely, a product marketed as an ophthalmic solution could present infringement risk if its formulation actually falls within the claimed viscosity range.

The claim does not expressly define the spindle, rotational speed or other detailed Brookfield test parameters in the text supplied. That issue could affect claim construction and reproducibility in litigation.

Which dependent claims create the greatest commercial risk?

Claims 2, 3, 4, 5, 8, 16, 17, 18, 19 and 20 create commercially relevant narrower positions.

Claim	Narrowing feature	Commercial significance
2	Polyacrylate above 0.2% to 3.0%	Covers common carbomer concentration ranges
3	Povidone above 0.8% to 10%	Targets povidone-containing systems
4	Bimatoprost below 0.01%	Relevant to low-dose products
5	Sorbitol, mannitol or glycerol at 1.2% to 5.5%	Covers common tonicity agents
8	Polyacrylate molecular weight of 1 to 4 million	Narrows polymer identity and performance
9	Preservative-free gel	Relevant to single-dose products
10	Benzalkonium chloride preservative	Relevant to multidose products
11	Benzalkonium chloride at 0.005% to 0.02%	Covers conventional preservative concentrations
16	Osmolality of 270 to 330 mOsm/kg	Focuses on near-isotonic products
17	pH adjusted to 7.3	Potentially important for products with a fixed target pH
18	Polyacrylate above 0.2% to 0.7%	Captures lower polymer levels
19	Povidone above 2.5% to 10%	Captures higher-povidone formulations
20	Bimatoprost below 0.0045%	Covers very low-dose formulations

Claims 4 and 20 are particularly relevant to products using less than 0.01% bimatoprost. A formulation containing 0.0040% bimatoprost could fall within both claims if all other requirements are met.

What bimatoprost concentrations are covered?

The independent claim covers bimatoprost from 0.003% through 0.03% by weight. The dependent claims establish narrower low-dose positions:

Claim 4: less than 0.01%.
Claim 20: less than 0.0045%.

The overlap is substantial. A product containing 0.004% bimatoprost would fall within the concentration limitations of claims 1, 4 and 20, assuming compliance with the remaining limitations.

The claims do not require 0.01% or 0.03% specifically. This matters because marketed bimatoprost solutions commonly use those strengths, while the patent also reaches lower-concentration gel products.

What polymers and excipients are protected?

Polyacrylate

The polyacrylate must exceed 0.2% by weight in claim 1. Claim 2 extends to concentrations above 0.2% through 3.0%, while claim 18 narrows the range to above 0.2% through 0.7%.

Claim 8 adds a molecular-weight limitation of 1,000,000 to 4,000,000. This range is consistent with high-molecular-weight carbomer-type rheology modifiers, although the claim language should be reviewed against the patent specification for the intended polymer definitions.

Secondary polymer

The claim permits one of five polymer classes. Povidone is the most commercially significant because claims 3 and 19 specifically narrow the scope around povidone concentrations.

A formulation containing both povidone and polyethylene glycol may still satisfy claim 1. The claim requires a qualifying member of the group, not an exclusive use of only one member.

Isotonizing agent

Claim 1 requires osmolality of 200 to 400 mOsm/kg. Claim 16 narrows this to 270 to 330 mOsm/kg. Claim 5 identifies sorbitol, mannitol and glycerol at 1.2% to 5.5%.

The osmolality limitation is functional and should be evaluated on the final product, not solely by calculating the theoretical contribution of each excipient.

pH and base

The broad pH range is 6 to 8. Claim 17 narrows the target to pH 7.3. Claim 6 specifies a base concentration of 0.1% to 0.8%, while claim 7 identifies trometamol.

A formulation using trometamol at a different concentration could still infringe claim 1 or claim 7 if the claimed pH and other limitations are met.

Are preservative-free and preserved products both covered?

Yes. The claims create separate product and packaging positions.

Preservative-free products

Claim 9 covers a gel with no preservative. Claim 12 covers a preservative-free gel in a single-dose container.

A competitor cannot avoid claim 12 merely by changing the container if the gel itself remains within claim 1 and is preservative-free. The single-dose limitation is an additional requirement, not a substitute for the formulation limitations.

Preserved multidose products

Claim 10 covers benzalkonium chloride as a preservative. Claim 11 narrows its concentration to 0.005% to 0.02%. Claim 13 covers a multidose plastic container containing the preserved gel.

The claim architecture is commercially practical: preservative-free single-dose delivery and preserved multidose delivery are addressed separately.

What manufacturing process does claim 14 protect?

Claim 14 protects a specific order of addition:

Dissolve the secondary polymer in water and heat while mixing.
Dissolve the base in water.
Dissolve bimatoprost, the isotonizing agent, the salt and other excipients in water, then disperse the polyacrylate.
Combine the third mixture with the first mixture.
Add the second mixture.
Add additional water.

This is a process claim, not merely a claim to the final composition. A manufacturer may avoid literal infringement if it uses a materially different sequence, even if the resulting gel has the same composition. That strategy carries risk under the doctrine of equivalents if the alternative process performs substantially the same steps in substantially the same way.

The claim also presents an evidence issue. Process infringement generally depends on manufacturing records, batch instructions, validation documents, employee testimony and laboratory analysis. Those facts may be difficult to establish without discovery.

What treatment method does claim 15 cover?

Claim 15 covers administering the claimed gel to a subject with elevated intraocular pressure and reducing that pressure.

The claim is limited by the formulation requirements of claim 1. A product that lowers intraocular pressure but does not meet the claimed gel composition does not literally satisfy claim 15.

The method claim may create risk for a manufacturer, distributor or healthcare provider when the product labeling expressly directs treatment of elevated intraocular pressure. Induced-infringement exposure depends on the product’s instructions, promotional materials and intended use.

When does US Patent 10,314,780 lose exclusivity?

The patent issued on June 11, 2019, and is expected to expire in approximately 2034 under the standard 20-year patent-term framework. The precise expiration date depends on the earliest effective nonprovisional filing date, any patent-term adjustment, terminal disclaimer and any patent-term extension reflected in the USPTO record.[1]

The patent is not a Hatch-Waxman regulatory exclusivity period. Patent expiration and FDA regulatory exclusivity are separate concepts. A patent may expire after an FDA approval, and a generic or follow-on product may face patent litigation before expiration even when regulatory exclusivity has ended.

There is no biologic component to bimatoprost. Biosimilar exclusivity rules therefore do not apply.

What is the Orange Book status of US 10,314,780?

The patent is directed to a bimatoprost gel formulation, not a conventional bimatoprost ophthalmic solution. Orange Book listing depends on whether the patent is submitted by the relevant approved-product sponsor and whether it claims the approved drug substance, drug product or method of use under FDA listing rules.[2]

A patent’s presence in the US patent database does not establish Orange Book listing. Conversely, the absence of a listing would not eliminate ordinary patent infringement risk.

The principal Orange Book landscape for bimatoprost has historically concerned approved ophthalmic solutions and patents associated with those products. A formulation patent directed to a drippable gel should be analyzed separately from patents covering conventional solution products, combination products or manufacturing processes.

Are Paragraph IV challenges likely?

A Paragraph IV certification is relevant only when a generic applicant files an ANDA referencing an approved product and certifies that an Orange Book-listed patent is invalid, unenforceable or not infringed.[2]

For US 10,314,780, the risk analysis depends on whether the patent is listed against an approved reference product and whether the proposed generic product is a gel matching the claimed formulation. A generic applicant pursuing a conventional aqueous bimatoprost solution would face a stronger noninfringement position if it does not meet the viscosity, polyacrylate and secondary-polymer limitations.

A gel generic designed to match the patented composition would face greater Paragraph IV and infringement exposure. The critical technical questions would include:

Whether the product contains more than 0.2% polyacrylate.
Whether its viscosity is at least 200 mPa·s.
Whether it contains one of the listed secondary polymers.
Whether final osmolality is within 200 to 400 mOsm/kg.
Whether the formulation uses the claimed salt and pH range.
Whether its manufacturing sequence falls within claim 14.

How does the patent compare with conventional bimatoprost patents?

Technology	Typical claim focus	Relationship to US 10,314,780
Bimatoprost active ingredient	Compound or prostamide structure	Earlier and broader chemical protection
Conventional ophthalmic solution	Concentration, preservatives, solution stability	May not meet the gel viscosity limitation
Combination glaucoma therapy	Bimatoprost with timolol or other agents	Separate product and method landscape
Sustained-release implant	Implant structure and controlled delivery	Technically distinct from a drippable gel
Bimatoprost gel	Polyacrylate, viscosity, polymer system and delivery container	Directly implicated by US 10,314,780
Manufacturing process	Order of addition and dispersion	Addressed by claim 14

The patent’s strength is greatest against a close-copy gel. It is weaker against a conventional solution, a low-viscosity formulation, a formulation using no qualifying secondary polymer, or a product outside the specified osmolality and pH ranges.

What generic launch scenarios exist?

Scenario 1: Conventional solution launch

A conventional bimatoprost solution may avoid the patent if it lacks the claimed polyacrylate concentration and viscosity. Separate Orange Book patents and regulatory requirements remain relevant.

Scenario 2: Low-viscosity gel launch

A product below 200 mPa·s may avoid literal infringement of claim 1, provided the measured viscosity is reliable and the product does not fall within another enforceable claim.

Scenario 3: Alternative rheology system

A formulation using a different thickener that is not a qualifying polyacrylate may reduce risk. The analysis must account for claim construction and equivalents.

Scenario 4: Preservative-free single-dose gel

This is the highest-risk design if it uses low-dose bimatoprost, high-molecular-weight polyacrylate, povidone, near-isotonic osmolality and a viscosity within the claimed range.

Scenario 5: Design-around using a different polymer

Replacing povidone with an excipient outside the Markush group could avoid claim 1, but the replacement must also preserve the intended viscosity, stability, ocular tolerability and delivery performance.

What is the patent strength of the estate?

The patent has meaningful formulation protection but does not create a complete monopoly over all bimatoprost ophthalmic products.

Its strongest features are:

Multiple overlapping concentration ranges.
Coverage of both preservative-free and preserved presentations.
Product, container, process and method claims.
Functional control through viscosity and osmolality.
Specific fallback claims for povidone, trometamol, benzalkonium chloride and high-molecular-weight polyacrylate.

Its principal vulnerabilities are:

Dependence on numerous cumulative limitations.
Potential measurement disputes concerning viscosity.
Design-around opportunities using alternative polymers or rheology systems.
Limited relevance to ordinary bimatoprost solutions.
Possible prior-art challenges involving ophthalmic gels, carbomers, povidone and prostamide therapies.

The estate is strongest as a blocking position against a close formulation copy and weaker as a broad barrier to all generic bimatoprost products.

What patent litigation, settlements and licensing deals affect the patent?

The patent record establishes the issued claims and prosecution history, but it does not itself establish a licensing agreement, settlement, covenant not to sue or commercial launch authorization.

No conclusion about a Paragraph IV settlement or license should be drawn solely from the patent number. Such agreements may be confidential, product-specific or limited to particular parties and jurisdictions. Any litigation assessment must distinguish:

Litigation involving US 10,314,780 itself.
Litigation involving earlier bimatoprost compound patents.
Litigation involving Orange Book-listed patents for approved solutions.
Proceedings involving related foreign family members.

Key Takeaways

US 10,314,780 is a formulation patent centered on a drippable bimatoprost ophthalmic gel.
Claim 1 requires all major elements together, including bimatoprost, more than 0.2% polyacrylate, a qualifying secondary polymer, 200 to 400 mOsm/kg osmolality and 200 to 2,000 mPa·s viscosity.
Claims 4 and 20 create focused protection for low-dose bimatoprost gels.
Claims 9 through 13 separately address preservative-free single-dose and preserved multidose products.
Claim 14 protects a defined manufacturing sequence.
Claim 15 covers treatment of elevated intraocular pressure using the claimed gel.
The expected patent term extends into approximately 2034, subject to the official term calculation.
A conventional bimatoprost solution may avoid the patent, but a close-copy carbomer or polyacrylate gel presents substantial infringement risk.
Biosimilar rules do not apply because bimatoprost is a small-molecule drug.
Paragraph IV exposure depends heavily on Orange Book listing and the existence of an ANDA referencing a relevant approved gel product.
The strongest design-around options involve viscosity, polymer identity, polyacrylate concentration, osmolality and the secondary-polymer system.

FAQs About US Patent 10,314,780

Does US 10,314,780 cover Lumigan?

Not automatically. Lumigan and other conventional bimatoprost solutions must be compared against every limitation, particularly the polyacrylate, secondary polymer and 200 to 2,000 mPa·s viscosity requirements.

Can a bimatoprost gel avoid the patent by using 0.002% active ingredient?

That concentration is below claim 1’s 0.003% lower limit. The product could still require review against other patents, regulatory requirements and potential equivalents theories.

Does using carbomer create automatic infringement?

No. Carbomer may qualify as a polyacrylate, but infringement also requires the claimed concentration, secondary polymer, osmolality, pH, salt, water and viscosity limitations.

Are single-dose preservative-free bimatoprost products specifically targeted?

Yes. Claims 9 and 12 address preservative-free gels and preservative-free single-dose containers, respectively.

Is the manufacturing process claim relevant if the final formulation is outside the patent ranges?

Generally, claim 14 depends on making the gel of claim 1. A process producing a formulation outside claim 1 may have a stronger noninfringement position, although the exact claim dependency and process evidence must be evaluated.

References

United States Patent and Trademark Office. (2019). US Patent No. 10,314,780, ophthalmic gel comprising bimatoprost. U.S. Department of Commerce.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. U.S. Department of Health and Human Services.
U.S. Food and Drug Administration. (2024). Abbreviated new drug application submissions: Patent certifications and suitability petitions. U.S. Department of Health and Human Services.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Thea Pharma	ZOLYMBUS	bimatoprost	GEL;OPHTHALMIC	217307-001	Sep 9, 2025		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial	Y			A METHOD OF TREATING A PATIENT WITH GLAUCOMA OR OCULAR HYPERTENSION	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2016277336	⤷ Start Trial
Brazil	112017026552	⤷ Start Trial
Canada	2985897	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Summary for Patent: 10,314,780